+
Lupin To Present Cancer Drug Data at ASCO 2025
ECONOMY & POLICY

Lupin To Present Cancer Drug Data at ASCO 2025

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:
4. Date: 2 June 2025
5. Time: 1:30–4:30 pm CDT
6. Location: Hall A, McCormick Place, Chicago
7. Abstract No.: 3107 | Poster Board No.: 422
8. Trial Registration: CTRI/2023/07/054753
9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.Presentation Details:4. Date: 2 June 20255. Time: 1:30–4:30 pm CDT6. Location: Hall A, McCormick Place, Chicago7. Abstract No.: 3107 | Poster Board No.: 4228. Trial Registration: CTRI/2023/07/0547539. DOI: 10.1200/JCO.2025.43.16_suppl.3107Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Next Story
Real Estate

No glass boxes!

India is moving away from the ‘glass box’ syndrome, all-glass façades that were widely used in commercial buildings in the last two decades but came at a significant environmental cost given the country’s predominantly hot and humid climate. Poor thermal performance, excessive heat gain and dependency on mechanical cooling systems made buildings with glass façades energy guzzlers and significantly increased their carbon footprint.That said, it’s important to be aware that “glass is not the enemy,” points out Heena Bhargava, Architect, Architecture Discipline. “How it ..

Next Story
Infrastructure Transport

Why do pavements fail?

India’s highways continue to expand at a healthy pace. But conversations on the surface quality of highways are growing louder because major deficiencies and black spots continue to be identified, and they are cause for concern.“Road surface roughness causes vehicle vibrations that, in turn, can affect the performance of drivers,” explains Dr V K Gahlot, Road Safety Auditor, Centre for Research and Sustainable Development (CfRSD). “Continuous exposure may induce fatigue, a contributory factor to road accidents. Road surface roughness also affects the vehicle operating cost...

Next Story
Infrastructure Urban

APAC Logistics Rents Fall for First Time Since 2020

Logistics rents across the Asia-Pacific region declined 0.4% year-on-year in H1 2025, marking the first annual drop since 2020, according to Knight Frank’s Logistics Highlights H1 2025 report. Despite global trade tensions and cautious occupier sentiment, India emerged as a standout performer, driven by robust manufacturing momentum and supply chain recalibration.Regional Trends and DivergenceWhile rents largely remained stable across most markets, regional differences became more pronounced:Mainland China continued to see rental declines, though the pace of decline moderated to 12.8% YoY, s..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?